0001753926-24-000318.txt : 20240215 0001753926-24-000318.hdr.sgml : 20240215 20240215201009 ACCESSION NUMBER: 0001753926-24-000318 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20240215 FILED AS OF DATE: 20240215 DATE AS OF CHANGE: 20240215 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Francis Knuettel II CENTRAL INDEX KEY: 0001433316 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-41964 FILM NUMBER: 24645512 MAIL ADDRESS: STREET 1: 205 NEWBURY ST STREET 2: SUITE 204 CITY: FRAMINGHAM STATE: MA ZIP: 01701 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Chromocell Therapeutics Corp CENTRAL INDEX KEY: 0001919246 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 863335449 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 685 US HIGHWAY ONE CITY: NORTH BRUNSWICK STATE: NJ ZIP: 08902 BUSINESS PHONE: 9176446313 MAIL ADDRESS: STREET 1: 685 US HIGHWAY ONE CITY: NORTH BRUNSWICK STATE: NJ ZIP: 08902 3 1 ownership.xml X0206 3 2024-02-15 0 0001919246 Chromocell Therapeutics Corp CHRO 0001433316 Francis Knuettel II C/O CHROMOCELL THERAPEUTICS CORPORATION 4400 ROUTE 9 SOUTH, SUITE 1000 FREEHOLD NJ 07728 0 1 0 0 Interim CEO, CFO, Treas & Sec Stock Options 22.68 2033-01-10 Common Stock 22223 I Camden Capital LLC Stock Options 22.68 2033-01-10 Common Stock 2778 I Camden Capital LLC Stock Options 22.68 2033-06-23 Common Stock 27778 I Camden Capital LLC The securities are held by Camden Capital LLC. The Reporting Person, as the manager of Camden Capital LLC, is deemed to be a beneficial owner of these securities. On January 10, 2023, Camden Capital LLC was granted stock options to purchase 22,223 shares of common stock at an exercise price of $22.68 per share. 2,223 shares of such options became exercisable on October 1, 2022, 2,223 shares of such options became exercisable on January 1, 2023, 2,223 shares of such options became exercisable on April 1, 2023, 2,223 shares of such options became exercisable on July 1, 2023, 2,223 shares were vested on October 1, 2023, 2,223 shares were vested on January 1, 2024, 2,223 shares will vest on April 1, 2024 and the remaining 6,662 shares of such options shall become exercisable in equal installments on a quarterly basis, subject to the Reporting Person's continued service to Issuer. The final installment shall become exercisable on January 1, 2025, subject to the Reporting Person's continued service to Issuer. On January 10, 2023, Camden Capital LLC was granted stock options to purchase 2,778 shares of common stock at an exercise price of $22.68 per share, which shall become exercisable upon the closing of Issuer's initial public offering. On June 23, 2023, Camden Capital LLC was granted stock options to purchase 27,778 shares of common stock at an exercise price of $22.68 per share, which shall become exercisable within thirty (30) days of the closing of Issuer's initial public offering. Exhibit 24 - Power of Attorney /s/ Francis Knuettel II 2024-02-15 EX-24 2 g084048_ex24.htm POWER OF ATTORNEY

Exhibit 24

POWER OF ATTORNEY

KNOW ALL BY THESE PRESENT, that the undersigned hereby constitutes and appoints Aaron M. Schleicher, Esq. and Chuanyang Jiang, Esq. of the law firm Sullivan & Worcester LLP, individually and not jointly, as the undersigned’s true and lawful attorneys-in-fact to:

(1)             prepare, execute in the undersigned’s name and on the undersigned’s behalf, and submit to the U.S. Securities and Exchange Commission (the “SEC”) an Application for EDGAR Access (Form ID), including amendments thereto, and any other documents necessary or appropriate to obtain codes and passwords enabling the undersigned to make electronic filings with the SEC of reports required by Section 16(a) of the Securities Exchange Act of 1934, as amended (the “Act”), or any rule or regulation of the SEC;

(2)             execute for and on behalf of the undersigned, in the undersigned’s capacity as an officer and/or director of Chromocell Therapeutics Corporation (the “Company”), any and all Forms 3, 4 and 5 required to be filed by the undersigned in accordance with Section 16(a) of the Act and the rules thereunder;

(3)             do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4 or 5, complete and execute any amendment or amendments thereto, and timely file such form with the SEC and any stock exchange or similar authority; and

(4)             take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned, pursuant to this Power of Attorney, shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact’s discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact’s substitute or substitutes, shall lawfully do or cause to be done by virtue of this Power of Attorney and the rights and powers herein granted. The undersigned acknowledges that no such attorney-in-fact, in serving in such capacity at the request of the undersigned, is hereby assuming, nor is the Company hereby assuming, any of the undersigned’s responsibilities to comply with Section 16 of the Act.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned’s holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorney-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 1st day of August, 2023.

    /s/ Francis Knuettel II
    Francis Knuettel II